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Background. The blood-brain barrier (BBB), blood-spinal cord barrier (BSCB), and blood-cerebrospinal fluid barrier (BCSFB)
control cerebral/spinal cord homeostasis by selective transport of molecules and cells from the systemic compartment. In the
spinal cord and brain of both ALS patients and animal models, infiltration of T-cell lymphocytes, monocyte-derived
macrophages and dendritic cells, and IgG deposits have been observed that may have a critical role in motor neuron damage.
Additionally, increased levels of albumin and IgG have been found in the cerebrospinal fluid in ALS patients. These findings
suggest altered barrier permeability in ALS. Recently, we showed disruption of the BBB and BSCB in areas of motor neuron
degeneration in the brain and spinal cord in G93A SOD1 mice modeling ALS at both early and late stages of disease using
electron microscopy. Examination of capillary ultrastructure revealed endothelial cell degeneration, which, along with
astrocyte alteration, compromised the BBB and BSCB. However, the effect of these alterations upon barrier function in ALS is
still unclear. The aim of this study was to determine the functional competence of the BSCB in G93A mice at different stages of
disease. Methodology/Principal Findings. Evans Blue (EB) dye was intravenously injected into ALS mice at early or late stage
disease. Vascular leakage and the condition of basement membranes, endothelial cells, and astrocytes were investigated in
cervical and lumbar spinal cords using immunohistochemistry. Results showed EB leakage in spinal cord microvessels from all
G93A mice, indicating dysfunction in endothelia and basement membranes and confirming our previous ultrastructural
findings on BSCB disruption. Additionally, downregulation of Glut-1 and CD146 expressions in the endothelial cells of the BSCB
were found which may relate to vascular leakage. Conclusions/Significance. Results suggest that the BSCB is compromised
in areas of motor neuron degeneration in ALS mice at both early and late stages of the disease.
Citation: Garbuzova-Davis S, Saporta S, Haller E, Kolomey I, Bennett SP, et al (2007) Evidence of Compromised Blood-Spinal Cord Barrier in Early and
Late Symptomatic SOD1 Mice Modeling ALS. PLoS ONE 2(11): e1205. doi:10.1371/journal.pone.0001205
INTRODUCTION
The central nervous system (CNS) is an immunologically
privileged zone, which is normally protected from entry of
immune cells and serum proteins by the blood-brain barrier
(BBB), blood-spinal cord barrier (BSCB), and blood-cerebrospinal
fluid barrier (BCSFB). These barriers are specialized structures of
the CNS that control cerebral/spinal cord homeostasis by selective
transport of molecules and cells from the systemic compartment
(reviewed in [1–7]). This control is possible due to the unique
structural elements of the microvasculature – endothelial cells of
brain capillaries and epithelial cells of the choroids plexus,
astrocyte end-feet, and pericytes. Brain (spinal cord) capillary
endothelial cells are distributed along the length of the vessels,
completely encircling the lumen and connected via adherens and
tight junctions. Adherens junctions support intercellular adhesion,
as tight junctions form a diffusion barrier for most blood-borne
substances. The basement membrane (i.e. basal lamina), surround-
ing the endothelial cells and pericytes, supports the abluminal
surface of the endothelium. The basement membrane, which
consists of laminin, fibronectin, collagens, and proteoglycans [8,9],
separates adjacent tissues, acting as a barrier to the passage of
macromolecules and cell migration. The astrocyte perivascular
end-feet ensheathing approximately 95% of the vessel wall appear
to have an important role for maintenance of the BBB [10]. Thus,
functional integrity of all BBB/BSCB elements is critical for
protection of the CNS from various harmful blood substances.
Impairment of the BBB occurs in various pathological CNS
conditions. Accumulation of collagen in vascular basement
membranes and focal necrotic changes in endothelial cells were
found in Alzheimer’s patients [11]. Degradation of the extracel-
lular matrix may be concomitant with BBB disruption and tissue
softening, setting the stage for the most pronounced forms of brain
swelling and leading to the development of severe cerebral edema
over subsequent hours and days in stroke patients (reviewed in
[12]). In multiple sclerosis (MS), which is characterized by
inflammatory lesions within the CNS, BBB disruption enables
leakage of the serum protein fibrinogen into the brain parenchyma
[13,14] and may precede myelin damage aggravating the
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BBB dysfunction in MS patients is apparent not only in focal
lesions but also in diffuse abnormalities in white matter which were
detected by postmortem MRI. BSCB breakdown was found in an
experimental model of traumatic spinal cord injury [16,17]. It has
been shown that spinal nerve lesions also alter BSCB function
[18]. Results of these studies showed increased microvascular
permeability leading to blood protein extravasation and the
formation of vasogenic edema that play important roles in the
pathophysiology of the diseased or injured spinal cord.
Amyotrophic lateral sclerosis (ALS) is a progressive degenerative
disease affecting motor neurons in the spinal cord, motor cortex
and brainstem that leads to paralysis and death within five years of
disease onset [19,20]. Although numerous hypotheses about the
etiology and pathogenesis of ALS have been proposed (reviewed in
[21–23]), increasing evidence points to immune system involve-
ment in ALS pathogenesis [24–27]. In the spinal cord and brain of
both ALS patients and animal models, the presence of T-cell
lymphocytes [25,28], deposits of IgG [29–32], complement
components C3 and C4 [29], and monocyte/macrophage and
dendritic cells [28,33,34] were observed that may have a critical
role in motor neuron damage. Recently, IgG was detected in the
perikarya of motor neurons of the lumbar spinal cord in mice after
intraperitoneal injection of IgG derived from sera of ALS patients
[31]. Moreover, the uptake of IgG in multivesicular bodies in
endothelial cells in the affected areas of the spinal cord was found
in both ALS patients and mice injected with human ALS IgG.
Additionally, significantly increased levels of albumin, IgG, and
C3c have been noted in the cerebrospinal fluid of ALS patients
[35–38]. These findings suggest that barrier permeability may be
affected in ALS. Recently, we showed disruption of the BBB and
BSCB in areas of motor neuron degeneration in the brain and
spinal cord in G93A SOD1 mice modeling ALS at both early and
late stages of disease using electron microscopy [39]. Examination
of capillary ultrastructure revealed endothelial cell degeneration,
which, along with astrocyte alteration, compromised the BBB and
BSCB. However, the effect of these alterations upon barrier
function in ALS is still unclear. The aim of this study was to
determine the functional competence of the BSCB in G93A SOD1
mice modeling ALS at different stages of disease.
RESULTS
Disease symptom progression in G93A mice
The G93A mice were monitored weekly for initial disease
symptoms and disease symptom progression by body weight and
extension reflex, beginning at 7 weeks of age. Body weights of
G93A mice gradually increased until 11 weeks of age and then
stabilized for 2 weeks (12–13 weeks of age). Tremor, an initial sign
of disease, was seen in some mice as early as 13 weeks of age. After
this time, mice consistently lost body weight due to muscle
atrophy. By 18 weeks of age, G93A mice had lost approximately
14% (p=0.06) of their 13-weeks-of-age body mass, dropping from
25.460.38 g to 21.860.55 g (Figure 1, A). Eighteen weeks old
G93A mice weighed 28% less than C57BL/6J mice of the same
age (p=0.007), which continued to maintain their body weights
until 20 weeks of age. Deterioration in extension reflex started to
appear in G93A mice at 13 weeks of age (Figure 1, B). During the
next 5 weeks, mice demonstrated slowly declining hindlimb
extension and by 18 weeks of age, showed no extension
(p,0.001) and exhibited hindlimb paralysis. Thus, G93A mice
at about 13 weeks of age showed initial signs of disease such as
tremor, weight loss, and reduced hindlimb extension. Terminal
stage of disease in these mice was observed at 17–18 weeks of age,
as demonstrated by complete hindlimb paralysis, significant
reduction of body weight and absence of hindlimb extension.
Motor neurons in the cervical and lumbar spinal
cords of G93A mice
Nissl body staining was performed to identify motor neuron
condition in the spinal cords of G93A mice in early and late stages
of disease. In control C57BL/6J mice, many healthy motor neurons
with large soma and neuritic processes were visible in the cervical
and lumbar ventral horn of the spinal cords at 12–13 weeks of age
(Figure 2A, Figure 3A) and 19–20 weeks of age (Figure 2B,
Figure 3B). In the cervical spinal cord of G93A mice, numerous
motor neurons with vacuolization were found at 13 weeks of age,
concurrent with initial disease symptoms (Figure 2C). When disease
symptoms progressed and mice were paralyzed, usually at 17–
18 weeks of age, the number of motor neurons had decreased and
motor neurons of various sizes displayed vacuolization (Figure 2D).
Only a few healthy motor neurons were identified at this time. More
dramatic changes in motor neuron condition were found in the
lumbar spinal cords of ALS mice. Most motor neurons in 13 week
old mice showed signs of degeneration (Figure 3C). In G93A mice at
17–18 weeks of age, the ventral horn was essentially devoid of motor
neurons (Figure 3D).
Fluorescent detection of Evans Blue in the cervical
and lumbar spinal cords of G93A mice
Evans Blue, the tracer used to assess disruption of the BSCB, was
injected into G93A mice at initial (13 weeks of age) and late (17–
18 weeks of age) stages of disease symptoms prior to euthanasia.
C57BL/6J mice were also administered the EB dye. In the cervical
spinal cord, EB was clearly detected within the blood vessels in the
control C57BL/6J mice at 12–13 weeks of age (Figure 4A, B, C)
or in the cross-sectioned capillaries at 19–20 weeks of age
(Figure 4D, E). Vascular leakage of EB was distinguished in
G93A mice with early disease symptoms (Figure 4F, G) and at
end-stage of disease (Figure 4H, I, J) when more EB extravasation
was noted. Interestingly, vessel permeability was perceived in both
initial (Figure 4F) and late (Figure 4I) symptomatic G93A mice. In
the lumbar spinal cord, EB dye was observed intravascularly in
control C57BL/6J mice at 12–13 weeks of age (Figure 5A, B) and
19–20 weeks of age (Figure 5C, D), similar to results in the cervical
spinal cord, while EB extravasation abnormalities were found in
G93A mice at 13 weeks of age (Figure 5E, F). Significant EB
diffusion into the parenchyma of the lumbar spinal cord from
many blood vessels was detected in G93A mice at end-stage of
disease, 17–18 weeks of age (Figure 5G, H). Considerable vessel
permeability was seen in early (Figure 5F) as well as late
(Figure 5G) symptomatic G93A mice. Thus, vascular leakage of
EB was detected in G93A mice not only at end-stage of disease but
also concurrent with early disease symptoms.
Immunochistochemical characteristics of basement
membranes, endothelial cells, and astrocytes in the
spinal cords of G93A mice
Immunofluorescent staining for laminin-1 (major non-collagenous
basement membrane glycoprotein) demonstrated well organized
microvasculature networks in the cervical and lumbar ventral horn
of the spinal cords in C57BL/6J mice at 12–13 weeks of age
(Figure 6A, Figure 7A) and 19–20 weeks of age (Figure 6B,
Figure 7B). In these control animals, many capillaries of different
calibers were visible by laminin detection. Conversely, a marked
reduction of labeled vessels was observed in both cervical and
BSCB in ALS Mice
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and late (Figure 6D, Figure 7D) stages of disease, suggesting a loss
of vascularization or disruption of vascular basement membrane
integrity. In some cervical spinal cord sections of G93A mice with
initial disease symptoms, blurred spots around capillaries were
apparent in the ventral horn of the spinal cord (Figure 6C),
probably due to vascular leakage.
Immunofluorescent staining for Glut-1 (glucose transporter 1)
showed high expression of Glut-1 in microvascular endothelia of
the cervical and lumbar ventral horn of the spinal cords in
C57BL/6J mice at 12–13 weeks of age (Figure 8A, B, H, I) and at
19–20 weeks of age (Figure 8C, J). The Glut-1 immunoreaction of
endothelial cells lining the many capillaries of different calibers
was low, or none, in both cervical and lumbar spinal cords of
G93A mice at early (Figure 8D, E, K, L) and late (Figure 8F, G,
M, N) stages of disease.
Immunohistochemically, endothelial cells (CD146) and astro-
cytes (GFAP) were of normal appearance in the cervical and
lumbar ventral horn of the spinal cords in the control C57BL/6J
mice at 12–13 weeks of age (data not shown) and 19–20 weeks of
age (Figure 9A, B; Figure 10A, B, C). Delineated astrocytes and
astrocytes with perivascular end-feet on the vessel wall were clearly
Figure 1. Characteristics of disease progression in G93A mice. (A) Body weight and (B) extension reflex of G93A and control C57BL/6J mice. G93A
mice at about 13 weeks of age showed initial signs of disease such as weight loss and reduced hindlimb extension. Terminal stage of disease was
observed at 17–18 weeks of age, as demonstrated by complete hindlimb paralysis, significant reduction of body weight and absence of hindlimb
extension. Arrows indicate the age of mice when euthanatasia was performed. The five pointed star in A indicates difference (p=0.06) in body
weights between G93A mice at 13 weeks of age and 18 weeks of age; the four pointed star indicates a significant difference (p=0.007) in body
weights between G93A and C57BL/6J mice at 18 weeks of age. The four pointed star in B indicates a significant difference in extension reflex
(p,0.001) between G93A mice at 13 weeks of age and 18 weeks of age.
doi:10.1371/journal.pone.0001205.g001
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partially revealed in the cervical spinal cord of G93A mice at
initial (Figure 9C, D) or late (Figure 9E, F) stages of disease.
Although CD146 antigen expression was detected in some
endothelial cells of early symptomatic G93A mice, indistinct
immunoreaction for CD146 was observed in G93A mice at end-
stage of disease. Additionally, swollen endothelial cells (Figure 9F)
were found in the cervical spinal cord of late symptomatic G93A
mice. A small number of delineated astrocytes were also noted. In
the lumbar spinal cord of G93A mice at initial (Figure 10D, E) and
late (Figure 10F, G) stages of disease, decreased or unclear CD146
antigen expression was noted in endothelial cells. Notably,
increased astrocyte activation in both cervical (Figure 9F) and
lumbar (Figure 10F, G) spinal cords was detected in G93A mice at
late stage of disease.
DISCUSSION
In the present study, we investigated the functional competence of
the BSCB in G93A SOD1 mice modeling ALS at different stages
of disease. We observed microscopic evidence of BSCB impair-
ment in cervical and lumbar spinal cords, areas of motor neuron
degeneration, of ALS mice at initial disease symptoms and, more
severely, at late stage disease. Our data show EB leakage in
cervical/lumbar spinal cord microvessels in G93A mice at early
(13 weeks of age) and late (17–18 weeks of age) stage disease. More
leakage was found in lumbar spinal cords of mice at terminal stage
disease. Additionally, basement membrane disruption was noted at
both early and late stage disease, as shown by the loss of laminin
staining in the G93A mice. Downregulation of Glut-1 and CD146
expressions in spinal cord endothelial cells was also found in G93A
mice at early and late stage disease and may relate to altered
endothelial lining leading to vascular leakage. Small numbers of
delineated astrocytes were also established. These results confirm
our previous ultrastructural findings [39] on disruption of the
BSCB showing functional incompetence of BSCB structural
elements in ALS mice.
Significant death of motor neurons in G93A mice occurs at the
onset of clinical disease (90 days) and by end-stage disease
(136 days), mice show up to a 50% loss of cervical and lumbar
motor neurons [40–42]. In G93A mice, motor deficits have been
observed in tests of muscle strength and coordination as early as
8 weeks of age [43]. These results extend those of our previous
studies [44–46], showing initial signs of disease, such as tremor,
Figure 2. Motor neurons in the cervical spinal cord of G93A mice at
early and late stage of disease (cresyl violet staining). In the cervical
spinal cord, many healthy motor neurons with large soma and neuritic
processes were identified in the control C57BL/6J mice at (A) 12–
13 weeks of age and (B) 19–20 weeks of age. In G93A mice, numerous
motor neurons with vacuolization (asterisks) were found at (C)
13 weeks of age and (D) decreased numbers of motor neurons were
noted in 17–18 week old mice. Motor neurons of various sizes displayed
vacuolization (asterisks). Scale bar on left side is 200 mm, right side is
50 mm.
doi:10.1371/journal.pone.0001205.g002
Figure 3. Motor neurons in the lumbar spinal cord of G93A mice at
early and late stage of disease (cresyl violet staining). In the lumbar
spinal cord, C57BL/6J mice at (A) 12–13 weeks of age and (B) 19–
20 weeks of age showed numerous motor neurons with strong Nissl
body staining. Most degenerated or swollen motor neurons (asterisks)
were found in G93A mice at (C) early (13 weeks of age) and (D) late (17–
18 weeks of age) stages of disease; most surviving motor neurons were
small. Scale bar on left side is 200 mm, right side is 50 mm.
doi:10.1371/journal.pone.0001205.g003
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about 13 weeks (90 days) of age. At this age, numerous
vacuolizated motor neurons were found in the cervical lumbar
spinal cord and most motor neurons in the lumbar spinal cord
showed signs of degeneration.
The primary BBB/BSCB function is control of the CNS
homeostasis by selective transport of molecules and cells from the
systemic compartment. Substances with a molecular weight higher
than 400 Da generally cannot cross the barriers by free diffusion.
However, certain endogenous large molecules, such as insulin,
leptin, transferrin, and insulin-like growth factors, enter the brain
from blood via specific endothelial carrier-mediated or receptor-
mediated transporters (reviewed in [1,2,4,47]). Recently, IgG was
detected in the perikarya of motor neurons of the lumbar spinal
cord in mice 24 hours after intraperitoneal injection of IgG
derived from sera of ALS patients [31]. The injected IgG was
found in the axon terminals of the lumbar ventral horn motor
neurons, localizing in the microtubules and rough endoplasmic
reticulum. Furthermore, IgG was similarly detected in spinal cord
motor neurons of ALS patients. There was also evidence of IgG
intake in endothelial cells in affected areas of the spinal cord in
both ALS patients and mice injected with human ALS IgG.
Figure 5. Evans Blue fluorescence in the lumbar spinal cord of G93A
mice at early and late stages of disease. In the lumbar spinal cord, EB
dye (red, arrowheads) was determined intravascularly in the control
C57BL/6J at (A, B) 12–13 weeks of age and (C, D) 19–20 weeks of age
similar to the cervical spinal cord. EB extravasation abnormalities were
found in G93A mice at (E, F) 13 weeks of age (red, arrows). (G, H)
Significant EB diffusion (red, arrows) into the parenchyma of the lumbar
spinal cord from many blood vessels was detected in G93A mice at end-
stage of disease (17–18 weeks of age). Arrowheads in F and G indicate
vessel permeability. Scale bar in A–H is 25 mm.
doi:10.1371/journal.pone.0001205.g005
Figure 4. Evans Blue fluorescence in the cervical spinal cord of G93A
mice at early and late stages of disease. In the cervical spinal cord, EB
was clearly detected within the blood vessels (red, arrowheads) in the
control C57BL/6J mice at (A, B, C) 12–13 weeks of age or (D, E) in the
lumen of vessels (brilliant green) at 19–20 weeks of age. In G93A mice,
vascular leakage of EB (red, arrows) was detected (F, G) at early
(13 weeks of age) disease symptoms and (H, I, J) at end-stage of disease
(17–18 weeks of age) when more EB extravasation was seen. Arrow-
heads in F and I indicate vessel permeability. Scale bar in A–J is 25 mm.
doi:10.1371/journal.pone.0001205.g004
Figure 6. Immunofluorescence staining for laminin in the cervical
spinal cord of G93A mice at early and late stages of disease. Many
blood vessels of different diameter were immunoreactive for laminin-1
(red) in the control C57BL/6J mice at (A) 12–13 weeks of age and (B)
19–20 weeks of age. In G93A mice at (C) initial or (D) late stages of
disease, capillaries appear to be less numerous. In some early
symptomatic G93A mice, (C) blurry spots around capillaries were
found. The nuclei in A–D are shown with DAPI. Scale bar in A, B, C, D is
200 mm; inserts a, b, c, d is 50 mm.
doi:10.1371/journal.pone.0001205.g006
BSCB in ALS Mice
PLoS ONE | www.plosone.org 5 November 2007 | Issue 11 | e1205Engelhardt et al. [31] suggest that ‘‘there may be multiple
antibodies targeting a variety of epitopes of motor neurons in
ALS’’. The molecular weight of IgG is 150,000 Da and it is
unlikely that these molecules could cross an intact brain capillary
endothelium even by receptor-mediated transcytosis. However,
Pirttila et al. [48] showed that insulin-like growth factor (IGF)-1,
IGF binding protein-2, or nitric oxide were not elevated in CSF of
ALS patients, suggesting that there is not a major disruption in the
BCSFB. In another report [49], an ALS mouse model with
a permissive BBB was created by crossing G93A mouse with the
mdr1a/b knockout mouse and showed that cyclosporine A (CsA),
which cannot cross an intact BBB, BSCB or BCSFB, reached the
CNS when delivered intraperitoneally into this combined mouse
model. Since the authors did not investigate BBB or BSCB
condition in the original transgenic G93A mice, it is possible that
disruption or dysfunction of these barriers occur in ALS. The
1200 Da molecular weight of CsA is much smaller than that of
IgG. Further investigation is needed to resolve this apparent
discrepancy in ability to cross the BBB/BSCB.
Our finding of Evans blue extravasion in early symptomatic
G93A mice may suggest that large molecules such as IgG and
other blood proteins appear in the spinal cord due to vascular
leakage, one possible mechanism accelerating motor neuron
damage. However, it is unclear if BBB/BSCB disruption appears
prior to motor neuron degeneration or as result of motor neuron
dysfunction. Also, differences between the BBB and BSCB in
endothelial protein concentrations may impact observed patho-
logical changes in G93A mice. It has been shown that
microvascular endothelial cells, isolated from murine spinal cord,
morphologically similar to BBB endothelial cells, express reduced
amounts of several prominent BBB proteins such as tight junction-
associated proteins ZO-1 and occluding, adherens junction-
associated proteins beta-catenin and VE-cadherin, and the efflux
transporter P-glycoprotein [50].
Reduction in immunofluorescent labeling of basement mem-
brane of affected G93A mice suggests possible membrane
disruption. The basement membrane is part of the extracellular
matrix and is composed of collagens, proteoglycans, elastin and
several glycoproteins, of which laminin is the most abundant [8,9].
Reduced laminin labeling was observed in cervical and lumbar
spinal cords of both early and late symptomatic G93A mice,
possibly indicating vascularization changes leading to capillary
wall permeability. Interestingly, Ono et al. [51] showed fragmen-
ted and widely separated collagen bundles in capillaries and
decreased amounts of collagen in postmortem posterior half of the
lateral funiculus and in the anterior horn of cervical enlargements
from patients with sporadic ALS. Although the role of these
aberrations in the pathogenesis of ALS remains to be determined,
the authors suggested that abnormalities of collagen in the
perivascular spaces of capillaries ‘‘may be secondary to neuronal
degeneration as a underlying mechanism in ALS’’.
Figure 7. Immunofluorescence staining for laminin in the lumbar
spinal cord of G93A mice at early and late stages of disease. Various
laminin-positive vessels (red) were observed in the control C57BL/6J
mice at (A) 12–13 weeks of age and (B) 19–20 weeks of age similar to
cervical spinal cord results. Fewer blood vessels were labeled in G93A
mice at (C) early or (D) end-stage of disease. The nuclei in A–D are
shown with DAPI. Scale bar in A, B, C, D is 200 mm; inserts a, b, c, d is
50 mm.
doi:10.1371/journal.pone.0001205.g007
Figure 8. Immunofluorescence staining for Glut-1 in the cervical and
lumbar spinal cords of G93A mice at early and late stages of disease.
Cervical spinal cord. High expression of Glut-1 (red) was determined in
endothelial lining of many blood vessels of various diameters in the
cervical spinal cord of the control C57BL/6J mice at (A), (B) 12–13 weeks
of age and (C) 19–20 weeks of age. In G93A mice at (D), (E) initial or (F),
(G) late stages of disease, immunoreaction for Glut-1 in the endothelial
cells appear to be low, or nonexistent. The nuclei in A–G are shown
with DAPI. Scale bar in A and E is 50 mm; B, C, D, F, G is 25 mm. Outline
of white dots indicates configuration of blood vessels. Lumbar spinal
cord. Similar to the cervical spinal cord, most Glut-1-positive endothelial
cells (red) were observed in the control C57BL/6J mice at (H), (I) 12–
13 weeks of age and (J) 19–20 weeks of age. Less Glut-1 expression was
found in G93A mice at (K), (L) early or (M), (N) end-stage of disease. The
nuclei in H–N are shown with DAPI. Scale bar in J, M, N is 50 mm; H, I, K,
L is 25 mm.
doi:10.1371/journal.pone.0001205.g008
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is mediated by glucose transporter isoform 1 (Glut-1) [52,53].
Glut-1 is associated mainly with the brain capillary endothelial
cells and is asymmetrically distributed between the luminal and
abluminal membranes [54]. This asymmetric intracellular pool of
glucose transporter may provide for rapid transport of glucose
across the abluminal plasmalemma to the brain parenchyma [55].
The alteration of Glut-1 may be related to the pathogenesis of
microvascular permeability as has been shown, for example, in
cerebral edema (reviewed in [56]). In the present study, we found
low and mostly absent expression of Glut-1 in capillaries of both
cervical and lumbar spinal cords of G93A mice at early and late
stages of disease. This downregulation of Glut-1 expression in the
endothelial cells of the BSCB may be related to altered endothelial
lining leading to vascular leakage. Alternatively, decreased Glut-1
expression may result from aggravated alterations of the BSCB in
G93A mice. Although additional experiments such as quantitative
analysis of Glut-1 distribution and density in the endothelial
plasma membranes are needed to elucidate the regulatory
mechanisms of Glut-1 expression in the spinal cord, the present
study indicates that alteration of Glut-1 could be involved in the
pathogenesis of ALS.
Another of our findings was that endothelia surrounding
capillaries were partially revealed by CD146 antigen expression
in the cervical and lumbar spinal cords of G93A mice at initial
and, more markedly, at late stages of disease. Moreover, small
numbers of delineated astrocytes were established. These results
may indicate that degeneration or, at least, partial dysfunction, of
non-neuronal cells in ALS occurs. Evidence of widespread
inflammatory reactions in ALS already exists. The presence of
monocyte/macrophage cells, activated microglia, and reactive
astrocytes was established in the spinal cord tissue of most ALS
patients [28,33,34,57,58]. In a mouse model of ALS, immune/
inflammatory responses [59,60] are present even before any
evidence of motor dysfunction [25,61]. Strategically, astrocytes are
located at the interface between the blood vessels and the brain as
well as in the spinal cord parenchyma, influencing both the entry of
blood cells into the CNS and the activity of invading cells once they
have entered the brain parenchyma (reviewed in [62,63]). It has
been shown that activated astrocytes and microglia ‘‘in response to
signals derived from the immune system or generated within the
CNS’’ produce various inflammatory molecules that may increase
the permeability of the endothelial cell barrier [10]. Inhibition of
microglia activation,forexample,asrecentlyshowninvitro and invivo
using minocycline, may protect the brain after ischemic stroke by
improving BBB viabilityandintegrity[64].It ispossible that glial cell
activation in ALS could lead to vessel leakage. Additionally,
decreased numbers of delineated astrocytes and their perivascular
end-feet at the blood capillaries could affect vessel permeability.
Thus, our results confirm our previous ultrastructural findings
on disruption of the BSCB showing functional incompetence of
BSCB structural elements in ALS mice. A breakdown in the BSCB
is clearly indicated by EB leakage in cervical/lumbar spinal cord
microvessels in G93A mice at early and late stages of disease.
Laminin labeling suggests that basement membrane of vessels in
the spinal cords of the diseased G93A mice may be affected.
Additionally, downregulation of Glut-1 and CD146 expressions in
Figure 9. Immunohistochemical staining for endothelial cells (CD146)
and astrocytes (GFAP) in the cervical spinal cord of G93A mice at
early and late stages of disease. (A, B) Normal appearance of
endothelial cells (green, arrowheads) and delineated astrocytes (red,
asterisk) was observed in the control C57BL/6J mice at 19–20 weeks of
age. Endothelia (green, arrowheads) surrounding capillaries were
partially revealed in G93A mice at (C, D) initial or (E, F) late stages of
disease. Note: increased astrocyte activation in the cervical spinal cord
(F, asterisks) was detected in G93A mice at late stage of disease. The
nuclei in A, C, and E are shown with DAPI. Scale bar in A, C, E is 50 mm;
B, D, F is 25 mm.
doi:10.1371/journal.pone.0001205.g009
Figure 10. Immunohistochemical staining for endothelial cells
(CD146) and astrocytes (GFAP) in the lumbar spinal cord of G93A
mice at early and late stages of disease. (A, B, C) Similar to cervical
spinal cord, endothelial cells (green, arrowheads) and astrocytes (red,
asterisk) in C57BL/6J mice at 19–20 weeks of age appeared normal. In
G93A mice at (D, E) early or (F, G) end-stage of disease, decreased
CD146 antigen expression by endothelial cells (green, arrowheads) was
observed. Note: increased astrocyte activation in the lumbar spinal cord
(F, G, asterisks) was detected in G93A mice at late stage of disease. The
nuclei in A, C, D, and F are shown with DAPI. Scale bar in A, C, D, F is
50 mm; B, E, G is 25 mm.
doi:10.1371/journal.pone.0001205.g010
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endothelial lining leading to vascular leakage. Degeneration of
astrocytes could influence BSCB integrity. Importantly, is BSCB
breakdown a primary or secondary mechanism to motor neuron
degeneration in G93A mice? Demonstrating BSCB disruption
prior to the onset of disease symptoms and other pathological
processes would indicate that BSCB disruption plays a primary
role in ALS pathogenesis.
MATERIALS AND METHODS
Animals
All described procedures were approved by the Institutional
Animal Care and Use Committee at USF and conducted in
compliance with the Guide for the Care and Use of Laboratory Animals.
Transgenic male mice B6SJL-TgN (SOD1-G93A) 1GUR (G93A;
Jackson Laboratories), over-expressing human SOD1, carrying the
Gly93RAla mutation, were used. Fourteen mice at 7 weeks of age
were assessed on sensitive indicators of degenerative state (body
weight and extension reflex). Six C57BL/6J male mice of the same
age were used as controls. All mice were maintained on a 12:12 h
dark:light cycle (light on at 06:00 hours). Room temperature was
23uC. Food and water were available ad libitum.
Characteristics of disease progression
Body weight was measured weekly throughout the study. Extension
reflex was also observed weekly, as we previously described [46].
Briefly,extensionofthehindlimbswasobservedwhilethemousewas
suspended by its tail. A score (0–2) was given to each mouse
indicating: normal (2), partial (1) or absent (0) hindlimb extension.
Eight G93A mice were euthanatized at initial signs of disease
(tremor, weight loss, and reduced hindlimb extension) at approxi-
mately 13 weeks of age, while six were allowed to reach the end-
point of hindlimb paralysis at 17–18 weeks of age, when they were
also euthanatized. Measures of body weight and extension reflex
wererecordedforC57BL/6Jmiceaccordingtothe samescheduleas
G93A mice. C57BL/6J mice were euthanatized at 12–13 weeks
(n=3) or 19–20 weeks (n=3) of age.
Evans Blue dye
EvansBluedye(EB,AldrichChemical),961 Da,wasusedasatracer
for assessing BBB disruption [65]. G93A mice with initial or late
stage disease and C57BL/6J mice were intravenously injected with
2% EB in saline solution via the jugular vein 30–40 min prior to
euthanasia. This surgical procedure was performed as we previously
described [46]. Briefly, mice were anesthetized with Isoflurane
delivered using a calibrated vaporizer equipped induction chamber
and nose cone and administered at 2–5% in O2 (2 L/min) to induce
anesthesiaand thendecreasedto2%tomaintainthe anesthesia.The
jugular vein was exposed and isolated using blunt dissection. The
vein was ligated and a 31-gauge needle, attached to a 100-ml
Hamilton syringe, was placed into the lumen of the vein and sutured
in place. Evans Blue was delivered (0.2 ml/100g, 40 ml/mouse)
during 2 min. The needle was withdrawn, the suture tightened, and
the incision closed with Vetbond.
Euthanatasia and tissue preparation
Euthanatasia of all mice was achieved under deep pentobarbital
anesthesia and perfusion was not performed to avoid mechanical
disruption of blood capillaries. The cervical/lumbar spinal cords
were removed, fixed in 4% paraformaldehyde (PFA) in 0.1 M
phosphate buffer (PB), pH 7.2, and then cryoprotected in 20%
sucrose in 0.1 M PB (pH 7.2) overnight. Coronal sections of the
cervical (C2–C3) and lumbar (L4–L5) spinal cords were cut at
30 mm in a cryostat.
Immunofluorescence staining
For identification of EB leakage, serial tissue sections of the spinal
cords were thaw-mounted on slides, washed with deionized water
to remove the freezing medium, and then rinsed several times in
phosphate-buffered saline (PBS). The slides were coverslipped with
Vectashield (Vector) and examined under an epifluorescence
microscope.
Some spinal cord tissues were used for immunofluorescent
analysis of the basement membrane (laminin), endothelial cells
(Glut-1, CD146), and astrocytes (GFAP). Briefly, sections of the
cervical/lumbar spinal cords were labeled with rat anti-mouse
laminin-1 (a and b chains) monoclonal antibody (1:50, Chemicon),
rabbit anti-mouse Glut-1 polyclonal antibody (1:100, Alpha
Diagnostic Int.), or double-stained with mouse monoclonal
CD146 (1:30, Chemicon) and rabbit polyclonal antibodies against
glial fibrillary acidic protein (GFAP, 1:500, Dako). The next day,
the slides were incubated for 2 hrs with appropriate secondary
antibodies conjugated to either rhodamine (1:1500, Alexa 594,
Molecular Probes) or FITC (1:500–700, Alexa 488, Molecular
Probes) and, after several rinses in PBS, coverslipped with
Vectashield or Vectashield with DAPI (Vector) and examined
under epifluorescence using an Olympus BX60 microscope.
Staining of motor neurons in the spinal cord
Coronal sections of the C2–C3 and L4–L5 spinal cords were
rinsed in PBS and then stained with 0.1% cresyl violet (30 sec) for
routine histological analysis of motor neurons. Sections were then
washed several times in deionized water, air-dried, dehydrated,
and coverslipped using Permount.
Statistical analysis
Data are presented as means6SEM. The nonparametric Mann-
Whitney unpaired test was used to compare medians.
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